Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
May 09, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
April 29, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, May 9, 2019 at 8:00 AM Eastern Time NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 14, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank
March 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
$46 million total raised in recent financings extends cash runway into at least 4Q 2021 Current financial position fully funds all five ongoing clinical trials NEW YORK, March 06, 2019 (GLOBE...
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
January 30, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies...
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
January 07, 2019 18:35 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Provides Year End 2018 Clinical Update
December 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019 Phase 3 results of AXS-05 in treatment...
Axsome Therapeutics to Present at Biotech Showcase 2019
December 18, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate
November 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
November 09, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...